Publication Date
12-1-2025
Journal
Hepatic Oncology
DOI
10.1080/20450923.2025.2494446
PMID
40308043
PMCID
PMC12051611
PubMedCentral® Posted Date
4-30-2025
PubMedCentral® Full Text Version
Post-print
Abstract
This was a narrative review of select studies published through September of 2024. We review the shift toward multi-dimensional scores such as HCC early detection screening (HES), GALAD, ASAP, and mt-HBT represents a significant advancement in biomarker research for hepatocellular carcinoma (HCC) detection. Unlike single biomarker approaches, these scores integrate various clinical and biochemical factors to enhance predictive accuracy by reflecting different complementary aspects of disease progression and HCC oncogenesis. Proper testing and validation of biomarker scores in phase 3 biomarker studies is essential before wide use can be recommended. We also review the comparative performance of biomarker scores in phase 3 studies. The new version of HES (HES V2.0) which includes AFP, AFP L3, DCP, and changes in their levels the past one year, if available, in addition to age, platelets, albumin, ALT and underlying liver disease etiology outperforms GALAD in detecting early-stage HCC with overall 6.7% higher sensitivity, and ASAP with 13.4%-18.0% higher sensitivity, both at fixed 90% specificity. HES V2.0 is a leading candidate biomarker score for prospective testing in clinical studies of early HCC detection.
Keywords
Liver cancer, surveillance, fibrosis, metabolic dysfunction, biomarkers, fatty liver
Published Open-Access
yes
Recommended Citation
Fouad Jaber and Hashem B El-Serag, "Hes V20 Surpasses Galad for Hcc Detection: A Review of Multi-Dimensional Biomarker Scores and Studies" (2025). Faculty, Staff and Students Publications. 5833.
https://digitalcommons.library.tmc.edu/baylor_docs/5833
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Hepatology Commons, Oncology Commons